The mechanistic target of
rapamycin (mTOR) is a rational target for
cancer treatment. While the mTORC1-selective
rapalogs have shown significant benefits in the clinic, antitumor response may be further improved by inhibiting both
mTORC1 and
mTORC2. Herein, we established target profile of a novel mTOR
kinase inhibitor (mTOR-KI) MTI-31 and employed it to study new therapeutic mechanism in
breast cancer. MTI-31 demonstrated a potent mTOR binding affinity with >5000 fold selectivity over the related PI3K family
isoforms. MTI-31 inhibited mTORC1- and
mTORC2 function at ≤120 nM in cellular assays or 5 mg/kg orally in
tumor-bearing mice. In a panel of
breast cancer lines, the antitumor efficacy of MTI-31 was dependent on HER2+ and/or PIK3CAmut (HER2+/PIK3CAmut) status of the
tumors and required mTORC2-specific modulation of Bim, MCL-1 and GSK3. Inactivation of Bim or GSK3 each attenuated apoptotic death resulting in mTOR-KI resistance. The antitumor response also required a suppression of lipid metabolism in
therapy-sensitive
tumors. Treatment with MTI-31 or
AZD8055 substantially reduced lipogenesis and
acetyl-CoA homeostasis, which was mechanistically linked to a blockade of mTORC2-dependent
glucose-to-
lipid conversion rate. We also found that the basal levels of
carnitine palmitoyltransferase 1A and
lipid catabolism were elevated in HER2+/PIK3CAmut breast cells and were inhibited upon mTOR-KI treatment. A CPT1A inhibitor
etomoxir mimicked MTI-31 action in selective downregulation of cellular
lipid catabolism. Co-treatments with MTI-31 and
etomoxir enhanced the suppression of
cyclin D1, c-Myc and cell growth in HER2+/PIK3CAmut
tumors. These new mechanistic findings provide a rationale for targeting
mTORC1 and
mTORC2 in HER2+/PIK3CAmut
breast cancer.